sp2 Magazine fulfills the needs of the global pharmaceutical and biotechnology community with its highly regarded editorial coverage of industry news and business and technological developments from drug discovery through to scale-up and commercialisation.

Published monthly, coverage includes technological advances that drive research and innovation, as well as product development through key topics including: discovery biology/chemistry, biomanufacturing, bioprocessing and fine chemistry. The sp2 audience is senior R&D executives to bench scientists from pharma, biotech and emerging pharma. (Tradepub.com)

sp2 Magazine is dedicated to keeping the global pharmaceutical and biopharmaceutical community up-to-date with the latest news, business and technology coverage spanning the entire drug discovery & development value chain.

sp2 includes exclusive content from industry leaders on:
APIs   
 Contract Research  
 Medicinal Chemistry
 Biocatalysis  
 Custom/Contract Manufacture  
 Peptides & Proteins
 Biologics  
 DNA/RNA Medicines  
 Process Development & Scale Up
 Biotech Drug Development  
 Fermentation/Cell Culture  
 Proteomics
 Cell-Based Assays  
 Genomics  
 Target Validation
 Custom/Contract Manufacture  
 High Throughput Screening   
 Chiral Technologies   Lab Automation/Analytical Equipment

Click Here, Get Free Subscription to sp2 Magazine

Qualify for Your Free Digital Subscription!

Geographic Eligibility: USA, Canada, Selected International

Publisher: Avakado Ltd.

Visit sp2 Magazine Website

Targeted exclusively at the life science industries, sp2 is the leading European based magazine reviewing the application of drug discovery and fine chemistry in the discovery, development and commercialisation of complex new drugs and agrochemical compounds.

sp2 is targeted at readers who are process, research and development professionals from the pharmaceutical, biopharmaceutical, biotechnology and agrochemical industries.

Welcome to the sp2 website where you can find out more about our magazine...

Comments (0)

Name

Email

Comment

smaller | bigger

Add Comment